Curix, part of the Demcon group, is developing groundbreaking technology for the treatment of life-threatening and debilitating neurological diseases. This new technology makes it possible to temporarily open the blood-brain barrier, addressing one of the biggest challenges in neurology. With this technology, drugs for brain tumors and neurodegenerative conditions, such as Alzheimer's and Parkinson's disease, can be delivered more efficiently. The participation of Twinning Participaties allows Curix to develop an injector system suitable for initial clinical studies in humans. “Our ultimate goal is to contribute to the development of improved treatments for neurological diseases”, says Peter Frinking, managing director and chief scientific officer at Curix.

Twinning participaties has invested in Curix to further develop our technology. Twinning is an investor who focusses on not only creating financial return, but also social return. Peter Frinking, managing director Curix adds: With Twinning's investment, we are working towards the first clinical evaluations. Twinning is not just an anonymous financier, but is genuinely involved and interested. Twinning published an article about our partnership.

As part of the ambitious European research initiative UNLOOC (Unlocking the data content of Organ-on-Chips), Curix is pioneering new methods for drug delivery to the brain, aiming to transform treatment approaches for neurological diseases such as Alzheimer’s and brain tumors.